Increased coronary risk for women with android obesity taking sex steroids is reviewed

	Tweet

The coronary risk for women with android obesity
who are taking sex steroids was recently reviewed in the journal Climacteric Reviewers in Denmark sought “to summarize recent findings providing mechanistic insight into why the relative presence of central to peripheral fat mass is a critical determinant of atherogenesis and why postmenopausal women with android obesity represent a risk population with increased susceptibility to the cardiovascular harm of estrogen plus progestin therapy (EPT).” L.B. Tanko and C. Christiansen from the Center for Clinical & Basic Research conducted a review of their own research “and related literature in PubMed.”

“In postmenopausal women, android obesity characterized by excessive upper-body combined with relatively poorly developed lower-body fat mass is frequently associated with insulin resistance, low-grade inflammation, and early Atherosclerosis. Underlying mechanisms involve disequilibrium between proinflammatory cytokines (high interleukin-6/C-reactive protein) and the anti-inflammatory adipokine (low adiponectin),” the researchers reported.

"Recent findings point out that women with abnormal glucose tolerance, a metabolic alteration closely linked to android adiposity, respond with increases in low-grade inflammation and accelerated atherogenesis to EPT that collectively may promote acute complications,” they stated. “We recently pointed out that a progestin could exert a dose-dependent inhibitory effect on circulating adiponectin.”

“Thus, when EPT is prescribed to women with android obesity, further decreases in the protective adiponectin pool may become critical and act as a promoter of thromboembolic complications via its effects on plaque formation and stability,” they advised. “Since android obesity is associated with the highest levels of free estradiol, women with this phenotype might not be trivial candidates for EPT.”

The authors concluded, “The herein summarized findings shed light on important interactions between sex steroids and body fat mass, with functional implications for cardiovascular risk. Since previous trials have not optimized the dose of the progestin for its effect on circulating adiponectin, utmost caution should be exercised in the prescription of available estrogen plus progestin therapies to women with android obesity and/or symptoms of the insulin resistance syndrome.”

Tanko and Christiansen published their report in Climacteric (Adipose tissue, insulin resistance and low-grade inflammation: Implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy. Climacteric, 2006;9(3):169-180).

For additional information, contact L.B. Tanko, Center for Clinical and Basic Research, Ballerup byvej 222, 2750 Ballerup, Denmark.

Publisher contact information for the journal Climacteric is: Taylor & Francis Ltd., 4 Park Square, Milton Park, Abingdon OX14 4RN, England.

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]